Open AccessP107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi‐Trial Analysis Based on Individual Patient Data
Author(s) -
Driessen Julia,
De Wit Fer,
Herrera Alex F.,
Zinzani Pier Luigi,
Lacasce Ann S.,
Cole Peter D.,
Moskowitz Craig H.,
Sanz Ramón. García,
Fuchs Michael,
Müller Horst,
Borchmann Peter,
Santoro Armando,
Schöder Heiko,
Zijlstra Josée. M.,
Hutten Barbara A.,
Moskowitz Alison J.,
Kersten Marie José
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890996.84518.13
Subject(s) - medicine , brentuximab vedotin , oncology , cohort , chemotherapy , refractory (planetary science) , progression free survival , propensity score matching , lymphoma , surgery , hodgkin lymphoma , astrobiology , physics